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Abstract
Imaging can provide quantitative assessment of radiation-induced normal tissue effects. Identifying
an early sign of normal tissue damage with imaging would have the potential to predict organ
dysfunction, thereby allowing re-optimization of treatment strategies based upon individual patients’
risks and benefits. Early detection with non-invasive imaging may enable interventions to mitigate
therapy-associated injury prior to its clinical manifestation. Further, successive imaging may provide
an objective assessment of the impact of such mitigation therapies. However, many problems make
application of imaging to normal tissue assessment challenging, and further work is required to
establish imaging biomarkers as surrogate endpoints of clinical outcome. The performance of clinical
trials where normal tissue injury is a clearly defined endpoint would greatly aid in realization of these
goals.
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1. Introduction
Radiation therapy (RT) may induce local tissue damage which in turn, depending on the
severity and the volume affected, may lead to organ dysfunction (Figure 1). Organ dysfunction
may be clinical (symptomatic) or sub-clinical (asymptomatic). When imaging to assess normal
tissue effects is quantitative, it can represent a useful imaging biomarker (Figure 1). Imaging
biomarkers are closely connected with anatomical, physiological and molecular changes that
characterize the radiation induced tissue damage or organ dysfunction. However, only when
imaging biomarkers are correlated to clinical endpoints, can they become surrogate
endpoints of clinical injury (Figure 1). Identifying an early sign of normal tissue damage with
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imaging would have the potential to predict organ dysfunction, thereby allowing re-
optimization of treatment strategies based upon individual patients’ risks and benefits.
However, some imaging biomarkers may prove to be overly sensitive and too non-specific to
be useful as surrogate endpoints.
Understanding of underlying pathophysiology of normal tissue damage, and the associated
molecular and cellular processes that lead to long term effects such as cell death and apoptosis,
can help identifying precursors of organ dysfunction, which can be explored as potential
imaging biomarkers1. However, because knowledge of the normal tissue effects is incomplete,
choice of imaging biomarkers is often pragmatic and markers may be identified without the
researcher’s understanding the underlying molecular mechanisms. Even with incomplete
understanding of underlying biology, imaging biomarkers may be successfully used as
surrogate endpoints of clinical injury. In addition, they may help to elucidate the spatial and
temporal development of underlying molecular processes that drive RT associated injury.
Choosing imaging techniques that are sensitive to early biological processes of normal tissue
damage is important.
Acute and late normal tissue injury occurs from a complex interaction between radiation-
induced death of parenchymal cells, damage to the supporting vasculature, and associated
inflammatory and fibrotic reactions. Long-term depletion of tissue-specific stem cells or
progenitor cells can lead to fibrosis, organ dysfunction, and necrosis1. This interaction between
basic cellular and molecular process and physiological expression divides imaging assessment
into two distinguished biological levels: (a) Imaging of anatomical (structural) changes in
affected organs, (b) Imaging of functional, molecular and cellular processes of RT-induced
injury. Topics related to these assessments and the potential for further research are discussed
here.
2. Current approaches and status of normal tissue toxicity imaging
2.1 Anatomical imaging
Radiation therapy commonly causes changes that can be detected by planar X-ray or CT
imaging. For example, in patients treated for lung or breast cancer, approximately 50–100%
and 0–63%, respectively, have radiologic evidence of lung damage via chest X-ray (CXR) or
CT2. These changes in imaging, however, do not necessarily correlate well with symptomatic
injury. Similarly, in the liver, radiologic changes are often evident post-RT either prior to, or
in the absence of, clinical symptoms3, 4. Post-RT CT and MRI can detect non-specific
morphologic abnormalities in the brain that may reflect RT-induced tumor or normal tissue
inflammation/necrosis, or surgery-induced changes (e.g. enhancement along the resection
margin)5. A principal limitation of defining injury in this manner is that injury is often identified
months to years following RT when any opportunity to intervene to ameliorate the effects has
likely been lost.
2.2 Functional and molecular imaging
Functional imaging may provide an in vivo model of RT effects on both tumors and normal
tissues. The potential advantage of functional and molecular imaging over anatomic imaging
is that it may be more physiologically and clinically important, and may better reflect
underlying pathophysiologic processes. Many functional and molecular imaging modalities
have been used to monitor normal tissue responses; the most common being
fluorodeoxyglucose (FDG) PET, though other isotopes have also been used (e.g. 15O for
monitoring of blood flow changes). SPECT is often used to measure perfusion but can also be
used to image radiolabeled receptors over-expressed in certain tumors. MRI has become useful
to assess functional metrics such as regional perfusion (i.e. in the heart), ventilation (i.e. in the
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lung) and metabolic states (i.e. with MR Spectroscopy). Functional MRI (fMRI) has the ability
of assessing regional brain activity in response to stimuli. Data for several organ systems such
as lung6–8, heart9–13, liver14, 15, brain16–19 and parotid20, 21 have already revealed correlations
of radiation dose with changes measurable by a variety of functional imaging modalities.
3. Opportunity and future for normal tissue toxicity imaging
3.1 Imaging as a precursor of injury manifestation
A large body of converging evidence, from histopathology, molecular biology, animal models
and clinical observations, suggests that RT-induced normal tissue injury is a dynamic and
progressive process1, 22. Given that it is extremely difficult to obtain human normal tissue after
irradiation for histological and biological analysis and for longitudinal examination, it is
important to establish in vivo functional and molecular imaging as a biomarker for early
assessment and prediction of delayed or late organ dysfunction. Preclinical experiments, which
can provide unique data on normal tissue injury dynamics, can be extremely helpful in this
process 23, 24.
Identifying an early sign or precursor of normal tissue damage, e.g., during or shortly after
the course of fractionated RT, could predict the delayed organ dysfunction. For example,
cardiac functional imaging may allow for early detection of treatment-associated dysfunction.
This is particularly important since these changes often do not manifest clinically for at least
10 years post treatment25. In patients treated for breast cancer, SPECT can detect myocardial
perfusion defects in the irradiated left ventricle that are associated with wall motion
abnormalities. However, there are no systematic changes in either ejection fraction or clinical
cardiac events. Similarly, although SPECT lung perfusion imaging has been used quantitatively
to relate changes in regional perfusion/ventilation (e.g. function) to the regional radiation
dose6–8, there is limited correlation between the sum of these regional injuries (i.e. the
integrated response) and changes in global lung function (e.g. pulmonary function tests).
Changes in MRI-defined gadolinium enhancement kinetics may be associated with different
phases of radiation pneumonitis26. Similarly, abnormalities in FDG PET studies may relate to
symptomatic pneumonitis, and provide an objective measure of inter-patient variability of
biological response27–29.
Re-optimization of treatment strategies based upon individual patients’ risks and benefits is
another area that could benefit from normal tissue toxicity imaging. For example, the basic
pathophysiology of RT-induced liver disease is venous occlusion. Symptoms generally occur
2 weeks to 2 months following completion of RT, and the clinical outcome ranges from mild,
reversible damage to death. Therefore, early monitoring of venous perfusion would have the
potential to select patients with pre-clinical signs of perfusion changes prior to the onset of
symptomatic RT-induced injury. It has been shown that the reduction in regional portal venous
perfusion during the course of radiation therapy and local dose distribution in the liver are two
independent predictors for regional portal venous perfusion dysfunction one month post-
RT14. Furthermore, it has been demonstrated that the regional liver venous perfusion
dysfunction is associated with overall liver function30. Other alternative re-optimization
strategy could be re-optimization of irradiation geometry based on local normal tissue
damage31; however, it is questionable whether the changes would be detectable early enough
to allow modification of already started treatment regimen.
3.2 Imaging as a biomarker
Imaging biomarkers are characteristics that can be objectively imaged as indicators of normal
biological processes, pathogenic processes, or pharmacologic responses to therapeutic
interventions. Imaging biomarkers as surrogate endpoints are imaging biomarkers that are
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intended to substitute for clinical endpoints. Surrogate endpoints are expected to predict clinical
benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic,
pathophysiologic, or other scientific evidence.
Imaging biomarkers should be discussed in the context of molecular biomarkers, which are
described in detail elsewhere (Bentzen et al, same issue). Molecular biomarkers have
biophysical properties, which allow their measurements in biological samples, like in plasma,
serum, cerebrospinal fluid or biopsy samples. Molecular biomarkers can detect molecular and
cellular changes with high sensitivity, but might not be very specific. For example, the
hematocrit or other blood counts can be a sensitive measure of marrow function. However,
they can also be affected by dysfunction caused by other conditions (e.g. bowel disease or
malnutrition affecting hematocrit). Further, molecular markers lack spatial information. Thus,
they may be useful in the realm of whole organ irradiation (e.g. blood counts for total body
irradiation or liver function tests for whole liver irradiation), but may not be sensitive for
regional organ effects. Similar limitations hold for molecular biomarkers obtained from biopsy
samples, which sample only few points in the organ, thus not being able to assess the regional
organ resoponse heterogeneity. On the contrary, imaging has the unique potential for detecting
the spatial distribution of the tissue damage that can lead to organ dysfunction. Common to
imaging and molecular biomarkers32 is that they may be used to identify patients at increased
or decreased risk for radiation treatment-related injury. In some settings, imaging and
molecular biomarkers may be synergistic, and their combined use may overcome inherent
limitations of each single approach, thereby increasing overall sensitivity and specificity of the
assessment.
Multiple obstacles lie in the path toward establishment of imaging biomarkers as surrogate
endpoints for assessment and prediction of clinical injury. Challenges for quantitative imaging
are discussed in the next section. Other obstacles include unknown temporal dynamics of RT-
induced injury, understanding of normal biology, and the relationship between early normal
tissue damage and late symptomatic organ dysfunction. In addition, RT is often combined with
chemotherapy and molecular targeted therapies, where normal tissue toxicity can result from
either modality separately or through a synergistic effect of combined therapies. New
knowledge about the mechanisms of normal tissue toxicity, and potential inhibition of the
effects, for example with anti-inflammatory compounds (e.g., inhibitors of prostaglandin and
leukotriene formation, NFkB and IL-1 signaling) might significantly affect RT-induced
toxicity management. Monitoring induction, resolution and mitigation of radiation-induced
toxicity will be essential in the development of clinically successful normal tissue preserving
strategies. Molecular imaging might be particularly useful to study and monitor these changes.
However, much work still needs to be done before relevant molecular probes are developed to
fully explore the potential that molecular imaging offers for questions relevant to human
clinical imaging..
3.3 Need for quantitative imaging of normal tissue toxicity
Imaging modalities and techniques, primarily developed with clinical diagnostic application
in mind, are often not quantitative enough to raise imaging to the level of a biomarker.. Imaging,
even though having a quantitative physical basis, is very often burdened with significant
uncertainties, preventing characterization of small changes that are characteristic of moderate
normal tissue injury. It is important that quantification is ensured through the whole procedure
– from image acquisition and image reconstruction to image analysis. The assessment of
imaging as either a biomarker or surrogate endpoint also requires quantitative clinical
endpoints. However, while imaging endpoints are usually continuous, most clinical endpoints
are dichotic. Using a continuous variable for measurement of an organ function, or stage of
injury, could improve statistical power for correlative analysis relating imaging to clinical
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events, thereby reducing the number of patients required for studies. While qualitative
diagnostic imaging does not carry the same value as quantitative imaging, it can still be useful
in the diagnosis of normal tissue effects (e.g. esophageal stricture seen on barium swallow,
cerebral edema on CT/MRI).
Clearly, these problems call for a wide cooperative effort among various governmental,
professional and industrial entities. Some of these efforts have already begun. Initial efforts
started within individual professional societies: Radiological Society of North America
(RSNA), American College of Radiology (ACR), American Association of Physicists in
Medicine (AAPM), Society of Nuclear Medicine (SNM), International Society for Magnetic
Resonance in Medicine (ISMRM); however, it was soon realized that the problems are too
significant to be solved by a single professional society. The first organized effort was initiated
by National Cancer Institute (NCI) and Association of American Cancer Institutes (AACI) in
2003. It lead to the formation of Image Response Assessment Teams (IRAT) with the purpose
to facilitate development of multi-disciplinary teams in NCI-designated comprehensive cancer
centers to advance the role of imaging in assessment of response to therapy. The IRAT project’s
primary objective was to increase collaboration between imaging scientists and oncology
investigators to enhance the use of quantitative anatomic, functional, and molecular imaging
endpoints in clinical therapeutic trials. The IRAT initiative is currently being augmented with
the efforts within Clinical and Translational Science Award (CTSA), particularly the Imaging
Working Group. The second large effort was a workshop “Imaging as a Biomarker: Standards
for Change Measurements in Therapy” organized by National Institute of Standards and
Technology (NIST) in 2006. It included US Food and Drug Administration (FDA),
Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of
Health (NIH), academia and societies. Key summary points from this workshop were: 1)
variability is too high in the multi-center trials that use imaging, 2) standards for imaging
clinical trials are lacking, and 3) sharing of imaging data is inadequate partially due to
insufficient infrastructure and under-developed processes. In 2008 the Quantitative Imaging
Biomarkers Alliance (QIBA) between drug and equipment industries and imaging societies
has been formed to develop and advance standards for the use of volumetric CT, FDG-PET,
and DCE-MRI in clinical trials. More organized efforts following from these initiatives are
underway warranting a significant shift from qualitative to quantitative imaging in the future.
While these efforts are important in making imaging quantitative and more useful, they do not
specifically address or consider RT-induced normal tissue toxicity imaging as an endpoint. In
order to make normal tissue imaging more successful, a more coherent effort should be initiated
between all interested parties: clinicians, physicists, radiobiologists, radiologists, their
representative societies, such as American Society for Therapeutic Radiology and Oncology
(ASTRO), European Society for Therapeutic Radiology and Oncology (ESTRO), American
Association of Physicists in Medicine (AAPM), Radiation Research Society (RRS), and
cooperative clinical trial groups such as Radiation Therapy Oncology Group (RTOG) and
European Organization for Research and Therapy of Cancer (EORTC). For example, a cross-
society task group could be formed to systematically approach normal tissue imaging, prepare
normal tissue imaging guidance documents, and share the expertise between the interested
parties. More collaborative clinical trials focusing on normal tissue imaging, as main or
secondary endpoints, should be initiated, optimally within one of the cooperative groups.
4. Conclusions
Imaging has been successfully used to assess radiation-induced injury within several organs.
The extent and severity of normal tissue damage has also been successfully related to clinically
observed changes in global organ dysfunction. Since current assessment of normal tissue
damage and organ dysfunction mostly relies on established anatomical and functional imaging
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techniques, the full potential of discovering and applying imaging biomarkers has not been
explored. Use of molecular imaging, even though potentially much more powerful in
identifying radiation-induced injury, has yet to be thoroughly investigated. New knowledge
and understanding of the onset, dynamics and resolution of RT-induced injury mechanisms
will likely lead to development of more specific molecular imaging techniques. There are many
questions that make application of imaging to normal tissue assessment challenging – we do
not know when to image and what to image and how imaging changes correlate to the clinically
observed effects. In addition, establishing imaging as a biomarker, particularly rising it to the
level of surrogate endpoints of clinically relevant outcome, is still relatively weak.
The answers to these questions will only be obtained by performing clinical trials that focus
on normal tissue injury, and include imaging as an investigative modality as well as one of the
endpoints. The importance of well-designed clinical trials where normal tissue injury is a
clearly defined endpoint is paramount. In addition, preclinical studies of RT-induced normal
tissue injury can greatly help understanding complicated patophysiology. As we better
understand the mechanisms of RT injury elucidated by such studies, we will be able to more
rationally plan radiotherapeutic management to minimize treatment related complications and
intervene in injury processes to maximally improve outcomes and QOL for our patients. The
establishment of imaging as a biomarker holds great promise for realization of these goals.
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Relation between normal tissue effects and their clinical manifestation, and role of imaging to
assess the effects.
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